Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.17 USD | +0.50% |
|
+3.81% | +39.90% |
24/05 | JPMorgan Adjusts Price Target on Cellebrite DI to $14 From $12, Maintains Overweight Rating | MT |
24/05 | Deutsche Bank Adjusts Price Target on Cellebrite to $15 From $13, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.90% | 248.56Cr | |
+17.82% | 3,28900Cr | |
+15.39% | 9.04TCr | |
+15.27% | 8.56TCr | |
+38.41% | 5.25TCr | |
-20.27% | 5.03TCr | |
+32.66% | 4.68TCr | |
+84.81% | 4.27TCr | |
-34.87% | 4.17TCr | |
-2.18% | 2.78TCr |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- Cellebrite's Q1 Non-GAAP Earnings, Revenue Increase